Prelude Therapeutics Inc
NASDAQ:PRLD
Intrinsic Value
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. [ Read More ]
The intrinsic value of one PRLD stock under the Base Case scenario is 4.24 USD. Compared to the current market price of 4.12 USD, Prelude Therapeutics Inc is Undervalued by 3%.
Valuation Backtest
Prelude Therapeutics Inc
Run backtest to discover the historical profit from buying and selling PRLD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Prelude Therapeutics Inc
Current Assets | 205.4m |
Cash & Short-Term Investments | 201.9m |
Other Current Assets | 3.4m |
Non-Current Assets | 41.7m |
PP&E | 37.4m |
Other Non-Current Assets | 4.3m |
Current Liabilities | 17.6m |
Accounts Payable | 5.3m |
Accrued Liabilities | 11.5m |
Other Current Liabilities | 800k |
Non-Current Liabilities | 18.7m |
Other Non-Current Liabilities | 18.7m |
Earnings Waterfall
Prelude Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-137.5m
USD
|
Operating Income
|
-137.5m
USD
|
Other Expenses
|
12m
USD
|
Net Income
|
-125.5m
USD
|
Free Cash Flow Analysis
Prelude Therapeutics Inc
PRLD Profitability Score
Profitability Due Diligence
Prelude Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Prelude Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
PRLD Solvency Score
Solvency Due Diligence
Prelude Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Prelude Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRLD Price Targets Summary
Prelude Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for PRLD is 5.92 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.
Ownership
PRLD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PRLD Price
Prelude Therapeutics Inc
Average Annual Return | 5.02% |
Standard Deviation of Annual Returns | 132.36% |
Max Drawdown | -98% |
Market Capitalization | 226.3m USD |
Shares Outstanding | 54 930 000 |
Percentage of Shares Shorted | 3.66% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.
Contact
IPO
Employees
Officers
The intrinsic value of one PRLD stock under the Base Case scenario is 4.24 USD.
Compared to the current market price of 4.12 USD, Prelude Therapeutics Inc is Undervalued by 3%.